Accutest makes strategic expansion into Latin America to support the growth of pharmaceutical sector

Aug 25 2015

Accutest Research Laboratories, a leading global Contract Research Organization (CRO), further pursues its strategic expansion into Latin America by opening offices and establishing operational presence in Brazil.

Market surveys clearly indicate that Brazil is one of the fastest growing pharmaceutical markets globally, with its huge population of more than 200 million, an investment friendly environment, an effective patent protection regime and a relatively low incidence of spurious drugs. The pharmaceutical market of Latin America's largest economy is projected to reach sales of up to USD 46 billion by 2018, growing at a CAGR of 12%.

By establishing offices and operations in Brazil, Accutest participates and shapes the potential of the Latin American CRO market and contributes to the growth of its pharmaceutical sector.

Accutest continues to be at the forefront of global CROs, performing clinical and BA/BE studies for submissions in all key regulated markets. The company strictly pursues the highest quality standards and has been following in every detail regulatory principles over thousands of studies.

Of its strong regulatory track record of 80+ accreditations/approvals from global regulatory agencies, 12 are from ANVISA, the regulatory body that oversees the registration, production and sale of drugs in Brazil.

Speaking on the expansion, Founder and CEO Dr. Satish Sawant stated, "Opening offices in emerging countries to support drug development is a key element of our expansion strategy. We have identified seven emerging countries to develop operational capabilities, and by opening offices in Brazil, Malaysia and Taiwan we have completed our current expansion phase."

"Our scientific competence, timely delivery, quality excellence and cost effectiveness have led Accutest to become one of the preferred CRO partners to pharmaceutical and biotechnology companies globally. Our dedicated regulatory team liaises with the regulators to ensure efficient management of approval processes, which has resulted in performing over 230 BA/BE studies for ANVISA submissions in Brazil alone until now," said Dr. Ashutosh Pudage, President - Bioanalytical on Accutest's accomplishments.

Superior quality, adherence to timelines and competitive costs are the three pillars of a successful CRO. During a preceding expansion phase, Accutest opened offices in the US and in the Netherlands. By adding emerging countries, especially in Latin America and in Asia, Accutest will gain additional benefits which will be passed on to its vast client base.